

Oscient Pharmaceuticals

[View the current Oscient Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/27723-Oscient+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bi corporate/27723-Oscient+Pharmaceuticals.html>)

Contact Details:

1000 Winter Street, Suite 2200

Waltham

Massachusetts

02451

United States of America

Tel: 781-398-2300

Fax: 781-893-9535

Email: investors@oscient.com

Oscient Pharmaceuticals Corporation is a commercial-stage biopharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).

Recent Publications by Oscient Pharmaceuticals:



- [Screening large-scale association study data: exploiting interactions using random forests.](#)
BACKGROUND: Genome-wide association studies for complex diseases will... 25th March, 2006
Oscient Pharmaceuticals, Inc, (formerly Genome Therapeutics Corporation),- BMC Genet. 2004 Dec 10;5(1):32. ([DOI Direct Link](#))
- [Identifying SNPs predictive of phenotype using random forests.](#)
There has been a great interest and a few successes in the identification... 13th May, 2005
Department of Human Genetics, Oscient Pharmaceuticals, Waltham,- Genet Epidemiol. 2005 Feb;28(2):171-82. ([DOI Direct Link](#))
- [SED, a normalization free method for DNA microarray data analysis.](#)
BACKGROUND: Analysis of DNA microarray data usually begins with a... 16th December, 2004
Oscient Pharmaceuticals Corporation, 100 Beaver St, Waltham, Massachusetts- BMC Bioinformatics. 2004 Sep 2;5:121. ([DOI Direct Link](#))

Press Releases on Oscient Pharmaceuticals:

Onyx Pharmaceuticals Announces December 2009 Investor Events	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25
Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference	25th November, 2009	Ardea Biosciences, Inc.	/PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper
iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering	25th November, 2009		DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals; service division and Pyxis Discovery announced today that they have signed a collaborative agreement
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www
Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www

BioNews Results for Oscient Pharmaceuticals



- [Oscient Pharmaceuticals Corp-Financial Company Report - research report released](#)
 PR inside: Nov 2 2009 1:49PM Matching: oscient pharmaceuticals

- [Oscient Pharmaceuticals Corp.-Deals & Alliances Report - research report released](#)
PR inside: Oct 29 2009 5:33PM Matching: oscient pharmaceuticals
- [Oscient Pharmaceuticals Corp-Therapeutic Competitors - research report released](#)
PR inside: Oct 28 2009 9:20AM Matching: oscient pharmaceuticals
- [Lupin consolidated net surges by 39% in Q2 to Rs 160 crore](#)
PharmaBiz: Oct 27 2009 8:28AM Matching: oscient pharmaceuticals
- [Cornerstone gets US Bankruptcy Court okay to acquire rights to antibiotic factive from Oscient](#)
PharmaBiz: Sep 7 2009 12:20PM Matching: oscient pharmaceuticals
- [Cornerstone Therapeutics Receives Approval To Acquire Commercial Rights To Antibiotic Factive](#)
Pharmaceutical Business Review: Sep 5 2009 1:58AM Matching: oscient pharmaceuticals
- [Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive](#)
Pharma Live: Sep 3 2009 12:48PM Matching: oscient pharmaceuticals

Oscient Pharmaceuticals Patents:



- 7517684- [Nucleic acid and amino acid sequences relating to Pseudomonas aeruginosa for diagnostics and therapeutics](#)
- 7129214- [Antibacterial compounds having a \(pyrrole carboxamide\)-\(benzamide\)-\(imidazole carboxamide\) motif](#)
- 7151161- [Human genes of chromosome 11q13.3](#)
- 7205146- [Nucleotide and amino acid sequences relating to respiratory diseases and obesity](#)
- 7241613- [Identification of Candida cell surface proteins and their uses](#)
- 7317001- [Use of ramoplanin to treat diseases associated with the use of antibiotics](#)
- 7407804- [Human genes relating to respiratory diseases and obesity](#)
- 7416849- [HBM variants that modulate bone mass and lipid levels](#)
- 7501118- [Human gene relating to respiratory diseases and obesity](#)
- 7504490- [Nucleic acid and amino acid sequences relating to Aspergillus fumigatus for diagnostics and therapeutics](#)
- 7090973- [Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

